

Special Issue

Rheumatism in 2023: New Challenges and Perspectives

Message from the Guest Editors

In the past, rheumatism (from Greek $\rho\acute{\eta}\mu\alpha\tau\iota\sigma\mu\acute{o}\varsigma$, “to suffer from a flux”) was the umbrella term used when referring to any of the vast group of inflammatory disorders affecting joints, tendons, or muscles. Nowadays, it is known that under this quite obsolete term, about 200 different diseases are classified, each one with its pathogenesis, natural history, diagnostic work-up, and therapeutic strategy. Moreover, every patient suffering from a rheumatic disease has their own characteristics which can differ from those of someone else affected by the same illness. Finally, overlap syndromes are possible, making the rheumatologist’s work even more challenging. The scope of this Special Issue is to delineate the latest advances in terms of differential diagnosis, patients’ typification, and tailored therapy in the world of rheumatic diseases. With this aim, we are looking for both comprehensive reviews and original research articles from authors dedicated to academical and clinical rheumatology.

Guest Editors

Dr. Arianna Damiani

Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy

Dr. Martina Orlandi

1. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

2. Department of Geriatric Medicine, Division of Rheumatology AOUC & Scleroderma Unit, University of Florence, Florence, Italy

Deadline for manuscript submissions

closed (5 December 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/155932

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).